RxSight, Inc. reported sales of $134.5 million for the year ended December 31, 2025, a decrease of 3.9% compared to $139.9 million in 2024. The company's gross profit increased by 4.1% to $103.0 million in 2025 from $98.9 million in the prior year. RxSight experienced a loss from operations of $48.2 million in 2025, compared to a loss of $36.9 million in 2024. The net loss for 2025 was $38.9 million, or $0.95 per share, compared to a net loss of $27.5 million, or $0.71 per share, in 2024.
The decrease in sales was primarily attributed to a reduction in Light Delivery Device (LDD) sales, which fell by 47% compared to the prior year. This decline was partially offset by a 12% increase in Light Adjustable Lens (LAL) sales, driven by the expansion of the company's LDD installed base. The increase in gross profit was primarily due to a favorable product mix, with LAL sales comprising a larger percentage of total revenue in 2025. Operating expenses increased by 11.3% to $151.2 million in 2025, driven by higher selling and marketing costs, research and development expenses, and stock-based compensation.
Key operational developments included the sale of 163 LDDs during 2025, bringing the total installed base to 1,134. The company also realigned its commercial structure by unifying its LAL sales and clinical support personnel into a single Customer Success Organization. As of December 31, 2025, RxSight had 461 full-time employees. Research and development expenses increased by 12.2% to $38.5 million in 2025, reflecting the company's continued investment in product enhancements and new product development.
Looking ahead, RxSight plans to grow its business by expanding its LDD installed base, driving increased utilization of LALs, strategically expanding its commercial organization and marketing activities, and investing in RxSight system enhancements and expanding indications. The company also intends to scale its business to achieve cost and production efficiencies and grow its commercial operations in international markets. RxSight believes its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations for at least the next 12 months, although it may opportunistically seek to raise additional capital to support expansion and pursue other business opportunities.
About RxSight, Inc.
RxSight, Inc. develops innovative ophthalmic solutions, notably the Light Adjustable Lens system, to enhance post-cataract surgery visual outcomes. Its proprietary technology allows surgeons to customize and optimize vision after implantation, addressing limitations of fixed-premium intraocular lenses. Serving ophthalmologists and patients worldwide, the company focuses on improving clinical results, patient satisfaction, and practice growth through advanced, adjustable lens technology.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.